422 related articles for article (PubMed ID: 26967720)
1. Prostate-specific membrane antigen positron emission tomography in prostate cancer: a step toward personalized medicine.
Bouchelouche K; Choyke PL
Curr Opin Oncol; 2016 May; 28(3):216-21. PubMed ID: 26967720
[TBL] [Abstract][Full Text] [Related]
2. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
3. Advances in prostate-specific membrane antigen PET of prostate cancer.
Bouchelouche K; Choyke PL
Curr Opin Oncol; 2018 May; 30(3):189-196. PubMed ID: 29465429
[TBL] [Abstract][Full Text] [Related]
4. Prospective comparison of whole-body MRI and
Sawicki LM; Kirchner J; Buddensieck C; Antke C; Ullrich T; Schimmöller L; Boos J; Schleich C; Schaarschmidt BM; Buchbender C; Heusch P; Rabenalt R; Albers P; Antoch G; Müller HW; Hautzel H
Eur J Nucl Med Mol Imaging; 2019 Jul; 46(7):1542-1550. PubMed ID: 30879122
[TBL] [Abstract][Full Text] [Related]
5. PSMA PET and Radionuclide Therapy in Prostate Cancer.
Bouchelouche K; Turkbey B; Choyke PL
Semin Nucl Med; 2016 Nov; 46(6):522-535. PubMed ID: 27825432
[TBL] [Abstract][Full Text] [Related]
6.
von Eyben FE; Picchio M; von Eyben R; Rhee H; Bauman G
Eur Urol Focus; 2018 Sep; 4(5):686-693. PubMed ID: 28753806
[TBL] [Abstract][Full Text] [Related]
7. Simultaneous
Eiber M; Weirich G; Holzapfel K; Souvatzoglou M; Haller B; Rauscher I; Beer AJ; Wester HJ; Gschwend J; Schwaiger M; Maurer T
Eur Urol; 2016 Nov; 70(5):829-836. PubMed ID: 26795686
[TBL] [Abstract][Full Text] [Related]
8.
Malaspina S; De Giorgi U; Kemppainen J; Del Sole A; Paganelli G
Radiol Med; 2018 Dec; 123(12):952-965. PubMed ID: 30116970
[TBL] [Abstract][Full Text] [Related]
9. New Clinical Indications for (18)F/(11)C-choline, New Tracers for Positron Emission Tomography and a Promising Hybrid Device for Prostate Cancer Staging: A Systematic Review of the Literature.
Evangelista L; Briganti A; Fanti S; Joniau S; Reske S; Schiavina R; Stief C; Thalmann GN; Picchio M
Eur Urol; 2016 Jul; 70(1):161-175. PubMed ID: 26850970
[TBL] [Abstract][Full Text] [Related]
10. [Significance and Value of PSMA Ligands in Prostate Cancer].
Gasch C; Körber S; Kremer C; Eiber M; Kratochwil C; Haberkorn U; Hohenfellner M; Hadaschik B; Giesel FL
Aktuelle Urol; 2017 Apr; 48(2):140-147. PubMed ID: 28511220
[TBL] [Abstract][Full Text] [Related]
11. Diagnostic accuracy of
Scheltema MJ; Chang JI; Stricker PD; van Leeuwen PJ; Nguyen QA; Ho B; Delprado W; Lee J; Thompson JE; Cusick T; Spriensma AS; Siriwardana AR; Yuen C; Kooner R; Hruby G; O'Neill G; Emmett L
BJU Int; 2019 Nov; 124 Suppl 1():42-49. PubMed ID: 31287613
[TBL] [Abstract][Full Text] [Related]
12. Initial Experience of (68)Ga-PSMA PET/CT Imaging in High-risk Prostate Cancer Patients Prior to Radical Prostatectomy.
Budäus L; Leyh-Bannurah SR; Salomon G; Michl U; Heinzer H; Huland H; Graefen M; Steuber T; Rosenbaum C
Eur Urol; 2016 Mar; 69(3):393-6. PubMed ID: 26116958
[TBL] [Abstract][Full Text] [Related]
13. PET/CT With
Giovacchini G; Giovannini E; Riondato M; Ciarmiello A
Curr Radiopharm; 2018; 11(1):4-13. PubMed ID: 29090673
[TBL] [Abstract][Full Text] [Related]
14.
Ceci F; Castellucci P; Graziani T; Farolfi A; Fonti C; Lodi F; Fanti S
Eur J Nucl Med Mol Imaging; 2019 Jan; 46(1):31-39. PubMed ID: 30350010
[TBL] [Abstract][Full Text] [Related]
15.
Calais J; Czernin J; Cao M; Kishan AU; Hegde JV; Shaverdian N; Sandler K; Chu FI; King CR; Steinberg ML; Rauscher I; Schmidt-Hegemann NS; Poeppel T; Hetkamp P; Ceci F; Herrmann K; Fendler WP; Eiber M; Nickols NG
J Nucl Med; 2018 Feb; 59(2):230-237. PubMed ID: 29123013
[TBL] [Abstract][Full Text] [Related]
16. [
Hirmas N; Al-Ibraheem A; Herrmann K; Alsharif A; Muhsin H; Khader J; Al-Daghmin A; Salah S
Mol Imaging Biol; 2019 Jun; 21(3):574-581. PubMed ID: 30215174
[TBL] [Abstract][Full Text] [Related]
17. Prospective Comparison of 18F-Fluoromethylcholine Versus 68Ga-PSMA PET/CT in Prostate Cancer Patients Who Have Rising PSA After Curative Treatment and Are Being Considered for Targeted Therapy.
Morigi JJ; Stricker PD; van Leeuwen PJ; Tang R; Ho B; Nguyen Q; Hruby G; Fogarty G; Jagavkar R; Kneebone A; Hickey A; Fanti S; Tarlinton L; Emmett L
J Nucl Med; 2015 Aug; 56(8):1185-90. PubMed ID: 26112024
[TBL] [Abstract][Full Text] [Related]
18. Heterogeneous Flare in Prostate-specific Membrane Antigen Positron Emission Tomography Tracer Uptake with Initiation of Androgen Pathway Blockade in Metastatic Prostate Cancer.
Aggarwal R; Wei X; Kim W; Small EJ; Ryan CJ; Carroll P; Cooperberg M; Evans MJ; Hope T
Eur Urol Oncol; 2018 May; 1(1):78-82. PubMed ID: 31100231
[TBL] [Abstract][Full Text] [Related]
19.
Farolfi A; Ceci F; Castellucci P; Graziani T; Siepe G; Lambertini A; Schiavina R; Lodi F; Morganti AG; Fanti S
Eur J Nucl Med Mol Imaging; 2019 Jan; 46(1):11-19. PubMed ID: 29905907
[TBL] [Abstract][Full Text] [Related]
20. Prostate-specific membrane antigen for prostate cancer theranostics: from imaging to targeted therapy.
Arsenault F; Beauregard JM; Pouliot F
Curr Opin Support Palliat Care; 2018 Sep; 12(3):359-365. PubMed ID: 29939893
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
